Inhibition of CD95/Fas activation is currently under clinical investigation as a therapy for glioblastoma multiforme and preclinical studies suggest that disruption of the CD95–CD95L interaction could also be a strategy to treat inflammatory and neurodegenerative disorders. Here, FASLG is linked to glioblastoma.